MORGANTOWN, W.Va. – The WVU Cancer Institute is enrolling patients in an innovative clinical trial to treat ovarian cancer.
Valerie Galvan Turner, M.D., gynecologic oncologist at the WVU Cancer Institute, will help lead the trial to evaluate the efficacy of varying dosages and combinations of the cancer medications pegylated liposomal doxorubicin (PLD), atezolizumab, and bevacizumab in the treatment of ovarian cancer.
“We are excited to bring this clinical trial to West Virginia and the WVU Cancer Institute,” Dr. Galvan Turner said. “This treatment has the potential to allow for more options for patients for whom other treatments may not be effective.”
The clinical trial is open to epithelial ovarian cancer patients whose cancer recurred less than one year after completing their first treatment or line of chemotherapy and are considered platinum resistant.
All participants will receive treatment, but the types of treatment will be randomly assigned.
“The WVU Cancer Institute is dedicated to expanding the field of knowledge of cancer treatment,” Galvan Turner said. “We hope this study will help advance the field and provide more options for patients with ovarian cancer.”
Physicians at the WVU Heart and Vascular Institute are encouraging members of the community to learn about heart valve disease and the importance of early detection as part of National Heart Valve Disease Awareness Day on Feb. 22.
Nathan Ferguson, 23, of Bluefield, had never been seriously ill before and did not suspect anything serious when he developed a sore throat and cough, which left him on a couch at the oil rig in St. Clairsville, Ohio, where he worked.
A new study by a team of researchers, including Mohamad Alkhouli, M.D., medical director of the structural heart program at the WVU Heart and Vascular Institute, used patient data to study the outcomes of patients who require percutaneous coronary intervention (PCI) after coronary artery bypass grafting (CABG) procedures before being discharged.